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A b s t r a c t  
The objective of this study was to develop sustained-release floating tablets of cefdinir (CFDN) using 
effervescent technique to prolong gastric residence time (GRT) and compare their pharmacokinetics 
with immediate release (IR) and conventional sustained release (SR) tablets. The tablets were 
designed using CaCO3 as gas-former and three grades of polyethylene oxide as release-retardants 
and further were evaluated for their physical characters, in vitro drug release and buoyancy studies. 
The optimized formulation (F3) was found to be physically stable when stored at 40 oC/75% RH for 3 
months. In vivo radiographic imaging of F3 revealed a mean GRT of 4.83 μ 0.57 h (n=3). 
Comparative pharmacokinetic study was performed for F3, IR and SR tablets of CFDN in humans. 
Based on in vivo performance, the difference between tmax, AUC0-¥, t1/2 and MRT of F3, IR and SR 
tablets were found to be statistically significant (p < 0.05). The difference between Cmax of F3 and IR 
tablet was statistically significant, but the Cmax of F3 and SR tablet was not statistically significant. 
The relative bioavailability of F3 was 1.71 fold to IR and 1.24 fold to SR. This improved 
bioavailability is due to the combined effect of sustained release and increased GRT.  
Keywords: Cefdinir, Gastroretentive floating tablets, Polyethylene oxide, Radiographic imaging, 
Pharmacokinetic study. 
 
Introduction 
The oral route remains the preferred route for the administration of 
therapeutic agents Due to the low cost of therapy and ease of 
administration there by leading to patient compliance. Conventional 
oral dosage forms provide a specific drug concentration in systemic 
circulation without offering any control over drug delivery. 
Controlled-release drug delivery systems (CRDDS) provide drug 
release at a predetermined, predictable, and controlled rate [1]. An 
important requisite for the successful performance of an oral 
CRDDS is that the drug should have good absorption throughout 
the gastrointestinal tract (GIT) to ensure continuous absorption of 
the released drug [2]. A major limitation in the oral controlled drug 
delivery is that not all drug candidates get uniformly absorbed 
throughout the GIT. 
Dosage forms that can be retained in the stomach are called as 
gastroretentive drug delivery systems (GRDDS) [3]. GRDDS can 
improve the controlled delivery of drugs that have an absorption 
window by continuously releasing the drug for a prolonged period 
of time before it reaches its absorption site thus ensuring its 
optimal bioavailability [4]. Garg et al., 2008 [5] classified the 
GRDDS into four main classes: (i) floating systems [6], (ii) 
expandable systems [7], (iii) bioadhesive systems [8] and (iv) high 
density systems [9]. Floating systems are of two types: (A)  
 
 
effervescent systems, depending on the generation of carbon 
dioxide gas upon contact with gastric fluids, and (B) non-
effervescent systems. The latter systems can be further divided 
into four sub-types, including hydrodynamically balanced systems 
[10], microporous compartment systems [11], alginate beads [12] 
and hollow microspheres/microballons [13]. In addition, super-
porous hydrogels [14] and magnetic systems [15] were described. 
As reported  [4], the floating drug delivery is of particular interest for 
drugs   which: (a) act locally in the stomach; (b) are primarily 
absorbed in the stomach; (c) are poorly soluble at an alkaline pH; 
(d) have a narrow window of absorption; and (e) are unstable in the 
intestinal or colonic environment. Cefdinir (CFDN) is a semi-
synthetic, third-generation broad-spectrum oral cephalosporin 
antibiotic, which is active against both Gram positive and negative 
bacteria. It is widely used to treat acute and chronic bronchitis, 
rhinosinusitis and pharyngitis. It is approved by U.S Food and Drug 
Administration in 1997. It has a biological half life of 1.6 h with 21ă
25% of oral bioavailability [16]. Further, the drug has poor aqueous 
solubility and is soluble in dilute hydrochloric acid [17]. Therefore, 
due to above characters, it becomes a good candidate for the 
development of GRDDS. 
The gastroretentive tablets of CFDN were not reported until now. 
The present investigation involved the preparation and in vitro/in 
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vivo evaluation of CFDN floating tablets by effervescent technique 
using a release retarding polymer, polyethylene oxide and a gas 
former, calcium carbonate (CaCO3). The optimized formulation 
exhibited excellent floating behaviour, sustained drug release and 
good physical stability when stored at 40 oC/75% RH for 3 months. 
Further, in vivo investigations were also conducted to determine 
mean gastric residence time and bioavailability in healthy human 
volunteers. 
Material and Methods  
Materials 
Cefdinir (CFDN) and Polyox WSR 1105 were received as generous 
gift samples from M/s Orchid Pharma Ltd., Chennai, India. 
Polyethylene oxide (PEO) polymers available commercially under 
the trade name of Polyox WSR (water soluble resins), are novel 
materials with unique properties. Cefadroxil was a generous gift 
sample from M/s Aurobindo Pharma. Ltd., Hyderabad, India. 
Polyox WSR 205 and Polyox WSR 303 were purchased from 
Colorcon Asia Pvt., Ltd, India. Calcium carbonate, microcrystalline 
cellulose (Avicel PH102), magnesium stearate and talc were 
purchased from S.D. Fine-Chem. Ltd., Mumbai, India. Acetonitrile, 
methanol and dichloromethane (DCM) HPLC grade were 
purchased from Merck Ltd., Mumbai, India. All other solvents and 
reagents used were of analytical grade. 
 
Methods 
Preparation of CFDN floating tablets 
Accurately weighed quantities (Table I) of CFDN, Polyox WSR 
205/WSR 1105/WSR 303, calcium carbonate and Avicel PH102 
were passed through a sieve no. 40 to get uniform sized particles, 
then they were taken in a mortar and triturated with the help of a 
pestle for 10 min. Then the mixture was transferred into a 
polyethylene bag and further mixed for 5 min to ensure a 
homogeneous mass. To the mixture, magnesium stearate and talc 
were added and continued the mixing for another 2 min. Finally, 
about 600 mg of each mixture was weighed and fed manually into 
the die of a 16 station punching machine (Riddhi, RDD3 
Ahmedabad, India) to produce the desired tablets using 13 mm 
flat- faced round punches. 
 
                                         Table 1. Composition (in mg) of CFDN floating tablets. 
Ingredients 
Formulation code 
F1 F2 F3* F4 F5 F6 F7 F8 F9 F10 F11 
Cefdinir 300 300 300 300 300 300 300 300 300 300 300 
Polyox WSR 303 120 100 90 80 - - - - - - - 
Polyox WSR 205 - - - - 100 120 140 160 - - - 
Polyox WSR 1105 - - - - - - - - 100 120 130 
Calcium carbonate 60 60 60 60 60 60 70 70 60 60 60
Avicel PH 102 108 128 138 148 128 108 78 58 128 108 98 
Magnesium stearate 6 6 6 6 6 6 6 6 6 6 6 
Talc 6 6 6 6 6 6 6 6 6 6 6 
Total tablet weight 600 600 600 600 600 600 600 600 600 600 600 
*Lead formulation used in pharmacokinetic studies. 
 
Preparation of immediate and conventional sustained 
release tablets of CFDN 
The conventional sustained release (SR) tablets of CFDN were 
prepared using CFDN 300 mg, Polyox WSR 80 mg, Avicel PH 102 
208mg, magnesium stearate 6 mg and talc 6 mg per tablet. CFDN 
immediate release (IR) tablets were prepared using 300 mg of 
CFDN, 288 mg of Avicel PH 102, 6 mg of magnesium stearate and 
6 mg of talc in each tablet. The tablets were prepared by direct 
compression using 13 mm flat- faced round punches. 
 
In vitro evaluation of the prepared tablets 
The prepared tablets were evaluated for uniformity of weight using 
20 tablets, hardness (Monsanto tester) using 6 tablets, thickness 
(Vernier caliperse) using 6 tablets, friability (Roche friabilator) using 
10 tablets, drug content using 10 tablets, in vitro buoyancy using 3 
tablets and in vitro dissolution studies using 3 tablets. The results 
were expressed as mean μ S.D. 
 
Floating lag time and total floating time 
Floating characteristics of tablets were determined in a United 
States Pharmacopeia (USP) dissolution apparatus ІІ (Electrolab, 
TDT-06T, Mumbai, India) in 900 ml of 0.1 N HCl at 37μ0.5 ĈC and 
50 rpm [18]. The floating lag time (FLT) as well as total floating 
time (TFT) were determined visually. The time required for the 
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tablet to rise to the surface of the dissolution medium and the total 
duration of floating were noted as FLT and TFT, respectively. 
 
Drug release studies 
The release of CFDN from the prepared tablets was studied using 
USP dissolution apparatus II (Electrolab, TDT-06T, Mumbai, India). 
The dissolution medium was 900 ml of 0.1 N HCl (pH1.2). The 
temperature was maintained at 37μ0.5 oC. The rotation speed was 
50 rpm. Five ml of aliquot was withdrawn at predetermined time 
intervals of 1, 2, 3, 4, 6, 8, 10 and 12 h. The medium was 
replenished with 5ml of fresh medium each time. Samples were 
filtered through a membrane filter (0.45 øm) and analyzed by using 
UV-Visible spectroscopy (Elico, SL 159, India) at λmax 280 nm. 
 
Kinetic modelling of drug release profiles 
The profiles of the in vitro release were fitted to different equations 
and kinetic models to explain the release kinetics of CFDN from the 
floating tablets. The model with the highest correlation coefficient 
(R2) was considered to be the best fitting one. In the present study, 
the in vitro drug release profiles were fitted to zero-order [19], first-
order [20], Higuchi [21] and Korsmeyer-Peppas kinetic models [22]. 
Zero-order: Qt = Q0 + k0t                              (1) 
First order: logC = logC0 ă k1t/2.303              (2) 
Higuchi: Qt = k2t1/2                                       (3) 
Qt/Q¥ = ktn                                                                                     (4) 
Where Q0, Qt and Q¥ are the amounts of drug dissolved at zero 
time, at time t and at ¥ time. C0 and C are the concentrations of the 
drug at zero time and at time t, and k0, k1, k2 and k refer to the rate 
constants obtained from the linear curves of the respective models, 
and n refers to the release exponent indicative of the mechanism of 
drug release. If the value of n is 0.5 or less, the release mechanism 
follows Fickian diffusion, while the higher values (0.5 < n < 1) 
indicates a non- Fickian model (anomalous transport). The non-
Fickian model corresponds to coupled diffusion/polymer relaxation. 
If the n-value is 1, the drug release follows zero order and case II 
transport. The Case II transport generally refers to the dissolution 
of the polymeric matrix due to the relaxation of the polymer chain. 
However, the mechanism of drug release is regarded as super 
case-II transport if n-values are higher than 1. This mechanism 
could result from increased plasticization at the relaxing boundary, 
i.e., gel layer [23].  
 
Physical stability studies 
Physical stability studies were conducted according to International 
Conference on Harmonization (ICH) guidelines [24]. One of the 
optimized formulations F3 was enclosed in polyethylene bottle and 
placed in a desiccator containing saturated sodium chloride 
solution (75% RH) [25]. The desiccator was stored at 40 oC for 3 
months. At predetermined time intervals, the tablets were 
examined for hardness, FLT, TFT, drug content and drug release. 
Finally, the tablets were tested for any statistical difference using 
the Students paired t-test, the differences were considered to be 
significant at p < 0.05. 
 
Preparation of tablets for in vivo radiographic studies 
To make the tablet of optimized formulation (F3) x-ray opaque, 85 
mg of the drug was replaced with barium sulphate (BaSO4) and all 
other ingredients were kept constant so that the tablet weight 
remained same. This amount was determined experimentally to 
allow x-ray visibility but not to hinder tablet buoyancy. The 
prepared tablets were characterized for their hardness, thickness, 
weight variation, friability, FLT and TFT. 
 
In-vivo evaluation of gastric residence time in healthy 
volunteers 
To determine the in vivo residence time of a GRDDS, a variety of 
techniques were used like x-ray, endoscopy, ԃ-scintigraphy [26]. In 
this study, x-ray technique was used to determine the gastric 
residence time of CFDN floating tablets. The protocol of 
radiographic studies on healthy human volunteers was approved 
by the Institutional Ethics Committee, University College of 
Pharmaceutical Sciences, Kakatiya University, India. In this study, 
three healthy male volunteers participated after giving informed 
written consent. The subjects weighed in between 60ă73 kg 
(67μ6.5 kg), in height from 170-176 cm (173.3μ3.0 cm) and in the 
age group of 24-25 years (24.3μ0.5 years). The study was 
conducted under the guidance of an expert radiologist. After 
overnight fasting, the volunteers were fed with low calorie food 
(100 g of bread). Half an hour later, a BaSO4-loaded floating tablet 
was given to every volunteer with a glass of water. During the 
study, the subjects were not allowed to eat but water was made 
available ad libitum. At different time intervals like, 0.5, 2.5, 4.5 and 
5.5 h, the volunteers were exposed to abdominal x-ray imaging in a 
standing position. The distance between source of x-rays and the 
subject was kept constant for all images. Thus, the observation of 
the tablet movements could be easily noticed [27]. The mean 
gastric residence time was calculated. 
 
Comparative bioavailability studies 
The bioavailability study protocol was approved by the Institutional 
Ethics Committee, University College of Pharmaceutical Sciences, 
Kakatiya University, Warangal, India. Nine healthy male volunteers 
participated in the study after giving the informed written consent. 
The mean age of volunteers was 24μ1 years, mean height was 
170.5μ6.5 cm and the mean body weight was 67.2μ10.6 kg. They 
were judged to be healthy based on medical history, physical 
examination, haematological and biochemical laboratory tests. The 
subjects were instructed to take no medicine for at least one week 
before and during the study period.  
A single dose, randomized, three-way cross-over study was 
designed with nine subjects in each treatment group. A one week 
washout period existed between treatments of the study. After 
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overnight fasting, in three study periods for each subject the 
assigned formulation (300 mg of Floating F3/IR/conventional SR) 
was administered orally with 240 ml of water. Blood samples (5 ml) 
were obtained from forearm vein using sterile disposable needle 
and collected into 10 ml sterile test tubes. The blood samples were 
collected at predetermined time intervals such as 0, 0.5, 1, 1.5, 2, 
3, 4, 6, 8, 12 and 24 h. Subjects received standard, uniform meals 
after 5 h of tablet administration. The samples were centrifuged 
immediately at 4000 rpm for 15 min and the separated serum was 
transferred into 2.5 ml of Eppendorf tubes and stored at î80 oC till 
the time of analysis. 
CFDN-serum concentrations were determined by reversed phase 
high performance liquid chromatography (R-HPLC) equipped with 
a pump model, Shimadzu, LC-10AT and an SPD-10A detector. 
Mobile phase used was 12:88 v/v of acetonitrile: 0.015M potassium 
dihydrogen phosphate (pH 3.8 adjusted with orthophosphoric acid) 
and pumped isocratically at 1 ml/min through a Hibar, Lichrospher 
(5 øm, 250 ï 4.6 mm) column. The UV-Visible detector was 
adjusted to 280 nm. The serum samples were extracted by liquid-
liquid extraction method. To 300 øl of serum, 600 øl ml of cold 
methanol, 100 øl of internal standard (Cefadroxil, 30 øg/ml) was 
added and vortexed for 3 min in an Eppendorf tube [28]. After 
mixing well, centrifuged for 15 min at 4000 rpm. Supernatant was 
collected and transferred into test tube. To this 2 ml of 
dichloromethane was added and vortexed for 3 min, then 
centrifuged at 7000 rpm for 15 min. About 20 øl of supernatant was 
injected into the HPLC system (Shimadzu, LC-10AT). 
 
Pharmacokinetic analysis 
The pharmacokinetic studies were carried out in healthy human 
volunteers for optimized floating (F3), IR and conventional SR 
tablets. The elimination rate constant (kE) was obtained from the 
least square fitted terminal log-linear portion of the plasma 
concentration-time profile curve. The peak plasma concentration 
(Cmax) and corresponding time to peak (tmax) were obtained 
directly from the observed individual drug serum concentration-time 
profiles. The area under the curve to the last measurable 
concentration (AUC0-t) was calculated by the linear trapezoidal 
rule. The area under the curve extrapolated to infinity (AUC0-¥) was 
calculated by equation [5]. 
 
AUC0-¥=AUC0-t+Ct/kE                (5) 
Where Ct is the last measured concentration. The mean residence 
time (MRT) of the drug and relative bioavailability (BA) of the 
formulations were calculated by the following equations. MRT = 
AUMC0-¥/ AUC0-¥.                                                              (6)  
Relative BA = AUC0-¥ of test/AUC0-¥ of reference                (7) 
Where, AUMC is the area under the first moment of the 
concentration-time curve [29]. 
Results and discussion 
Physicochemical characteristics of prepared tablets 
The physicochemical characteristics of the tablets are summarized 
in Table II. The hardness of all tablet batches ranged from 5.12 μ 
0.40 to 5.28 μ 0.30 kg/cm2 and that of thickness from 4.13 μ 0.022 
to 4.17 μ 0.027 mm. All the tablet formulations showed acceptable 
physicochemical properties and complied with the pharmacopoeial 
specifications for weight variation, drug content and friability [30]. 
The weight of the tablets ranged from 598.3 μ 7.80 to 601.7 μ 8.34 
mg. Drug content results were found to be good among different 
batches; the percentage of drug content ranged from 98.29 μ 1.18 
to 101.39 μ 1.61. The percentage friability for all formulations was 
less than 1%, indicating good mechanical resistance. 
 
Floating lag time and total floating time 
 In this study, calcium carbonate was used as a gas-generating 
agent in order to aid floating of tablets. The in vitro testing revealed 
the ability of most formulations to maintain buoyant for more than 
10 h. This suggested that the gel layers formed by the investigated 
polymers enabled efficient entrapment of the generated gas 
bubbles. The possible increase in tablet porosity made it to float on 
the test medium (0.1 N HCl) for extended period of time. The 
calcium carbonate induced CO2 generation in the presence of 
dissolution medium. The generated gas was entrapped and 
protected within the gel formed by hydration of the polymer. This, 
decreased the density of the tablet below 1 gm/ml, and the tablet 
became buoyant [4]. As shown in Table II, all the formulations 
floated with a lag time of less than 1 min. The FLT of the 
formulations F1-F4, prepared with different concentrations of 
Polyox WSR 303 with constant calcium carbonate ratio (10% w/w), 
ranged from 12 μ 2 to 15.67 μ 2.52 s and that of formulations F5-
F8, prepared with Polyox WSR 205, ranged from 13.3 μ 3.0 to 23.0 
μ 6.2 s had no significant effect. The FLT of formulations F9-F11, 
prepared with Polyox WSR 1105 (100, 120 and 130 mg/tablet), 
showed in the range of 8 μ 2 to 12.3 μ 2.5 s. In all the formulations, 
as the concentration of polymer increased, the FLT was decreased 
and TFT increased, but the difference in FLT was not statistically 
significant. 
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                                       Table 2. Physicochemical characters of CFDN floating tablets. 
Formulation 
code 
Hardness 
(kg/cm2) 
Thickness    
(mm) 
Tablet 
weight (mg)  
Friability   
(%) 
Floating lag 
time (s) 
Floating 
duration     
(h) 
Drug content  
(%) 
F1 5.18μ0.29 4.14μ0.042 598.30μ7.80  0.32 15.67μ2.52 >12  98.29μ1.18 
F2 5.14μ0.24 4.16μ0.042 599.90μ7.77  0.37 14.33μ2.08 >12  99.65μ1.68 
F3 5.18μ0.35 4.17μ0.027 601.00μ5.72  0.41 12.33μ2.52 >12  100.51μ1.38 
F4 5.24μ0.40 4.15μ0.035 601.70μ8.34  0.43 12.00μ2.00 10  99.82μ1.26 
F5 5.22μ0.29 4.15μ0.035 599.70μ6.75  0.45 13.33μ3.06 6  99.48μ1.21 
F6 5.18μ0.23 4.14μ0.042 600.80μ5.87  0.39 14.67μ2.52 8  99.65μ1.04 
F7 5.28μ0.30 4.14μ0.044 600.80μ6.86  0.34 17.67μ2.53 10  99.65μ1.26 
F8 5.20μ0.32 4.13μ0.027 599.60μ5.91  0.32 23.00μ6.24 >12  101.39μ1.61 
F9 5.14μ0.36 4.13μ0.029 600.40μ6.52  0.36 8.00μ2.00 8  99.65μ1.24 
F10 5.12μ0.40 4.13μ0.022 599.50μ7.03  0.33 9.00μ3.00 10  101.36μ1.32 
F11 5.14μ0.39 4.13μ0.024 600.90μ6.49  0.32 12.33μ2.52 >12  99.31μ2.17 
 
Drug release studies 
Initially, we calculated the theoretical drug release profile of a 
CFDN floating tablets for 12 h [31]. The calculation was based on 
the pharmacokinetic parameters of the drug. It was expected that 
the developed formulation should have the theoretical drug release 
profile as 16% in 1h, 23% in 2 h, 31% in 3 h, 39% in 4 h, 54% in 6 
h, 69% in 8 h, 87% in 10 h and 100% in 12 h. In vitro dissolution 
studies of all the formulations of CFDN tablets were carried out in 
0.1 N HCl (pH 1.2). The study was performed for 12 h and 
cumulative drug release was calculated. The drug release profiles 
of the formulations, F1-F4 prepared with Polyox WSR 303 are 
shown in Figure 1. It was observed that the polymer Polyox WSR 
303 had a sustaining effect on the release of drug from the floating 
matrix tablets of CFDN. The effect of Polyox WSR 303 
concentration (120 mg, 100 mg, 90 mg and 80 mg/tablet) on drug 
release was evaluated. As the concentration of Polyox WSR 303 
was decreased, the drug release from the floating tablets was 
significantly increased. The maximum drug released from the 
formulations F1-F3 was 80.49 μ 1.08%, 88.06 μ 0.93% and 101.23 
μ 1.27% in 12 h respectively. The maximum drug released from the 
formulation F4 was 98.11 μ 1.64% in 10 h and it was unable to 
sustain the drug release for desired period of time. The differences 
in the release might be due to the amount of gel layer formed on 
the surface of the tablets. Formulation F3 was considered as best 
formulation among all the four formulations as it showed good 
sustained release very near to theoretical release profile. 
The drug release profiles of the formulations F5-F8, prepared with 
Polyox WSR 205 are shown in Figure 2. Formulations F5-F7 
sustained the drug release for only 6, 8 and 10 h respectively. This 
is because a sufficient polymer concentration in the hydrophilic 
matrix system is required to form a uniform gel barrier around the 
tablet upon hydration. 
 
 
 
 
 
 
 
Figure 1. Drug release profiles of cefdinir floating tablets prepared 
with Polyox WSR 303  (n = 3). Standard deviation bars are not 
visible (< 3%). 
 
This barrier is expected to prevent the drug from immediate release 
into the dissolution medium. If the polymer concentration is too low, 
a complete gel layer may not form resulting in a significant amount 
of drug being released too quickly or in the worst case, tablet 
disintegrate [32]. Figure 2 shows that an increased PEO level in 
the formulation resulted in a decreased drug release rate. 
Maximum drug released from formulations F5, F6, F7 and F8 were 
found to be 97.92 μ 1.54%, 99.24 μ 1.36%, 100.42 μ 1.39% and 
99.69 μ 1.54% in 6, 8, 10 and 12 hours respectively. Formulation 
F8 sustained the drug release for desired period of time and 
matched with the theoretical release profile. 
The results of the in vitro dissolution studies of the formulations F9-
F11, prepared with Polyox WSR 1105 are shown in Figure 3. 
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Maximum drug released from formulations F9, F10 and F11 were 
97.15 μ 1.7%, 96.30 μ 1.32% and 99.61 μ 1.43% in 8, 10 and 12 h 
respectively. When the Polyox WSR 1105 was less than 120 
mg/tablet, the CFDN floating tablets could not retain the physical 
integrity for desired period of time. Formulations F9 and F10 were 
unable to sustain the drug release for the desired time. Formulation 
F11 was able to sustain the drug release for desired period and 
followed the theoretical release profile 
. 
 
 
Figure  2. Drug release profiles of cefdinir floating tablets prepared 
with Polyox WSR 205 (n = 3). Standard deviation bars are not 
visible (< 3%). 
Figure 3. Drug release profiles of cefdinir floating tablets prepared  
with Polyox WSR 1105  (n = 3). Standard deviation bars are not 
visible (< 3%). 
Kinetic modeling of drug release profiles 
The dissolution profiles of all the formulations of CFDN were fitted 
to different kinetic equations. The values of n with corresponding 
correlation coefficients (R2) for all the formulations are shown in 
Table III. Formulations F5 and F6 followed the Higuchi model due 
to highest regression coefficient value, R2 = 0.991 and 0.992 
respectively. Formulations F1-F4 and F7-F11 followed the Peppas 
model and R2 values were ranged from 0.986-0.999. The 
optimized formulation F3 with highest regression coefficient values 
(R2) was predicted by Peppas model (0.995), when compared to 
zero (0.992), first order (0.528), and Higuchi models (0.954). The 
value of release exponent n for all the formulations ranged from 
0.588 to 0.805 and that of optimized formulation was 0.750. All the 
formulations have n values between 0.5 and 1, indicating 
anomalous transport (non-Fickian). The relative complexity of the 
prepared formulations indicated that the drug release was 
controlled by more than one process i.e., a coupling of diffusion 
and erosion. In controlled or sustained release formulations, 
diffusion, swelling, and erosion are the three most important rate 
controlling mechanisms followed. The drug release from the 
polymeric system is mostly by diffusion and is best described by 
Fickian diffusion. However, in the case of formulations containing 
swelling polymers, other processes in addition to diffusion play an 
important role in exploring the drug release mechanisms. The 
release rate constants (k) of all the formulations were significantly 
different. The value of k for formulations F1-F4, prepared with 
Polyox WSR 303, was ranged from 5.97-6.74, formulations F5-
F11, prepared with Polyox WSR 205, was ranged from 2.69-5.78 
and that of formulations F9-F11, prepared with Polyox WSR 1105 
was ranged from 5.47-6.42. Higher k values meant higher 
quantities of drug released. 
 
Physical stability studies 
The prepared CFDN floating tablets containing Polyox WSR 303 
(F3) was selected for stability study based on physical characters 
and in vitro drug release. The stability study was conducted for 3 
months. Before and after conducting the stability studies for 3 
months, the results were analysed statistically by using StudentÊs 
paired t-test. No significant difference (p > 0.05) was observed in 
the tablet hardness, FLT, TFT, drug content or in vitro dissolution 
(Table IV). The FLT was slightly increased from 12.33 μ 2.51 s to 
15 μ 2.64 s after storage for 3 months at 40 oC under 75% RH. 
But the difference was not statistically significant (p > 0.05). Thus, 
the F3 floating tablets of CFDN were stable for at least 3 months 
under these storage conditions. 
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Pharmacokinetic analysis 
 In this study, the pharmacokinetics of CFDN floating tablets were 
compared with IR and conventional SR tablets. The bioavailability 
study was conducted according to the protocol. The drug was well 
tolerated with no other symptoms or disturbances during the three 
study periods. The plasma samples were analyzed by HPLC 
method. The retention time of internal standard cefadroxil and drug 
was 3.8 and 8.8 min respectively. The mean serum concentration-
time curves of the three CFDN formulations are shown in Figure 5. 
The pharmacokinetic parameters of the three formulations are 
summarized in Table V. The significance of the difference between 
the treatments was evaluated by one-way analysis of variance 
(ANOVA) using GraphPad Prism (version 5.04, 2010) by DunnettÊs 
Multiple Comparison Test. The differences between formulations 
were considered to be significant at p < 0.05 with 95% confidence 
intervals.  
 
Table 5. Pharmacokinetic parameters of three formulations of 
CFDN (300 mg, single dose) (n = 9). 
Pharmacokinetic 
parameter 
CFDN 
conventional 
IR tablets 
Mean μ SD 
CFDN 
conventional 
SR tablets 
Mean μ SD 
   CFDN 
floating 
 tablets          
 Mean μ SD 
Cmax (øg ml-1) 2.05 μ 0.31* 1.54 μ 0.15** 1.48 μ 0.15**
tmax (h) 2.66 μ 0.50* 3.44 μ 0.52* 4.22 μ 0.66*
AUC0-t (øg ml-1 h) 9.39 μ 1.12* 13.48 μ 1.23* 16.51 μ 1.41*
AUC0-¥ (øg ml-1 h) 9.95 μ 1.11* 13.67 μ 1.25* 17.08 μ 1.57*
t1/2 (h) 2.30 μ 0.17* 3.43 μ 0.28* 4.21 μ 0.56*
MRT (h) 5.11 μ 0.26* 7.25 μ 0.40* 8.78 μ 0.61*
* Statistically significant (p < 0.05).  
** Statistically not significant (p > 0.05). 
 
 
The results showed that the difference between all 
pharmacokinetic parameters of IR and floating tablets of CFDN 
were statistically significant (p < 0.05). The peak plasma 
concentration (Cmax) of IR tablets was 2.05 μ 0.31øg ml-1 and that 
of floating tablets 1.48 μ 0.15 øg/ml. The tmax of floating tablets 
(4.22 μ 0.66 h) was significantly delayed when compared with the 
IR tablets (2.66 μ 0.50 h), indicating the better sustained release 
character of floating tablets. The AUC0-¥ of the IR and floating 
tablets were found to be 9.95 μ 1.11 øg h ml-1 and 17.08 μ 1.57 øg 
h ml-1 respectively. The higher AUC0-¥ of CFDN floating formulation 
may be due to slower release rate or the prolonged gastric 
residence time. The IR tablets exhibited shorter t 1/2 (2.30 μ 0.17 h) 
than floating tablets (4.21 μ 0.56 h). MRT values for IR and floating 
formulations were 5.11 μ 0.26 and 8.78 μ 0.61 h respectively. 
Similarly, the difference between all pharmacokinetic parameters of 
conventional SR and floating tablets of CFDN were statistically 
analysed and the results showed that the Cmax of conventional SR 
tablets (1.54 μ 0.15 øg ml-1) was slightly greater than that of 
floating tablets (1.48 μ 0.15 øg ml-1) of CFDN, but the difference 
was not statistically significant. And the difference between tmax, 
AUC0-¥, t ó and MRT were found to be statistically significant (p < 
0.05). The relative bioavailability was found to be 1.71 times to that 
of IR tablets and is significant, but not very significant when 
compared to SR tablets as it was 1.24 times. This improved 
bioavailability is due to the combined effect of sustained release 
and increased GRT of CFDN floating tablets. 
Conclusions  
The floating tablets of CFDN were successfully developed using 
Polyox WSR 303, Polyox WSR 205 and Polyox WSR 1105 by 
effervescent floating technique. The optimized formulation (F3) 
showed satisfactory results with respect to FLT, TFT and sustained 
drug release, and was physically stable during 3 months period. 
The non-Fickian diffusion was the release mechanism from all the 
prepared tablets. The in vivo radiographic studies showed that the 
BaSO4-loaded floating tablets were retained in the stomach for 
4.83 μ 0.57 h (n=3). Formulation F3 increased the bioavailability 
when compared to IR and conventional SR formulations of CFDN. 
The increased relative bioavailability was 1.71 fold to IR and 1.24 
fold to conventional SR tablets. This improved bioavailability is due 
to the combined effect of sustained release and increased GRT of 
CFDN floating tablets.  
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Figure  5. Plasma concentration-time profiles of IR, conventional 
SR and floating tablets of CFDN (n = 9).  
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